Chromosome 14 linkage analysis and mutation study of 2 serpin genes in allergic asthmatic families

J Allergy Clin Immunol. 2001 Apr;107(4):654-8. doi: 10.1067/mai.2001.113865.

Abstract

Background: Genome and chromosome screens reported DNA markers on chromosome 14 linked to allergic asthma or intermediate phenotypes in several populations.

Objective: We sought to perform a linkage study on chromosome 14 and a further association study on candidate genes mapped in the region found to be linked to allergic asthma or intermediate phenotypes.

Methods: The study consisted of a sample of 189 families (847 genotyped individuals) from a restricted geographic area in northeastern Italy. The subjects were characterized for the following phenotypes: allergic asthma, total serum IgE levels, skin prick test responses, and bronchial hyperresponsiveness (BHR) to methacholine. Genotyping was done with 14 DNA markers and 4 polymorphisms in the genes encoding alpha(1)-anti-trypsin and alpha(1)-antichymotrypsin (ACT).

Results: Multipoint analysis indicated a potential linkage of BHR with marker D14S617 (nonparametric linkage z score = 2.32, P =.01). Transmission disequilibrium of Thr -15Ala in the gene encoding ACT was observed with all the phenotypes investigated: allergic asthma, BHR, total IgE levels, or skin prick test responses (P =.041,.02,.0053, or.026, respectively).

Conclusion: Chromosome 14 screening and transmission disequilibrium testing on the gene encoding ACT suggest that it or a closely located gene may be involved in susceptibility to allergic asthma in the Italian population.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Asthma / genetics*
  • Child
  • Child, Preschool
  • Chromosomes, Human, Pair 14*
  • Genetic Linkage*
  • Humans
  • Hypersensitivity / genetics*
  • Middle Aged
  • Mutation*
  • alpha 1-Antichymotrypsin / genetics*
  • alpha 1-Antitrypsin / genetics*

Substances

  • alpha 1-Antichymotrypsin
  • alpha 1-Antitrypsin

Grants and funding